Suchergebnisse

Wall Street analysts expect AbbVie (ABBV) to post quarterly earnings of $2.69 per share in its upcoming report, which indicates a year-over-year increase of 9.4%. Revenues are expected to be

AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.62 per share. This compares to earnings of $2.46 per share a year ago. These figures are

For the quarter ended March 2026, AbbVie (ABBV) reported revenue of $15 billion, up 12.4% over the same period last year. EPS came in at $2.65, compared to $2.46 in the year-ago quarter.

The

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute

AbbVie ABBV stock is currently trading below its 50-day and 200-day simple moving averages (SMAs). A stock trading below both its 50-day and 200-day simple moving averages is generally viewed as

AbbVie ABBV is set to report first-quarter 2026 results on April 29, before the opening bell. While the immunology segment is expected to remain the company’s primary growth driver, the oncology

AbbVie ABBV is set to report first-quarter 2026 earnings on April 29, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.78 billion and $2.69 per share

AbbVie ABBV announced that the FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval of its fast-acting short-duration toxin

AbbVie ABBV announced that it has submitted a regulatory filing to the FDA seeking approval for a new indication of its blockbuster immunology drug, Rinvoq (upadacitinib). The filing seeks approval

AbbVie Inc. ABBV reported first-quarter 2026 adjusted EPS of $2.65, which beat the Zacks Consensus Estimate of $2.62. The reported figure also exceeded the company’s guidance of $2.56-$2.60 issued

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.14 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of

Abbott (ABT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.09 per share a year ago. These figures are

Abbott (ABT) reported $11.16 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 7.8%. EPS of $1.15 for the same period compares to $1.09 a year ago.

The

Abbott Laboratories ABT reported first-quarter 2026 adjusted earnings per share (EPS) of $1.15, which surpassed the Zacks Consensus Estimate by 0.6%. The figure improved 5.5% from the prior-year

Founded in 1929, Lord Abbett managed assets worth more than $ 250 billion as of March 31, 2026. This privately held company has around 184 investment professionals with an average of 18 years of

Investors in Abbott Laboratories ABT need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $70 Call had some of the highest implied

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the